Specifying GMP Drug Substance Manufacturing for a RAS(ON) Multi-Selective Inhibitor Candidate: A Request-for-Proposal Framework for Test Article Supply Supporting FDA IND Submission
Nonclinical studies submitted to FDA are only as credible as the test article administered to the animals. This article builds a request for proposal (RFP) for a contract development and manufacturing organization (CDMO) to produce one GMP-compliant batch of drug substance for a hypothetical oral RAS(ON) multi-selective inhibitor candidate, in support of a downstream in vivo genotoxicity study and future IND-enabling work. The RFP specifies a 2.0 kg batch with a stated justification, release specifications aligned with ICH Q3A, Q3C, and Q3D, analytical procedures governed by ICH Q2(R2) and Q14, a stability program under ICH Q1A(R2) for refrigerated storage, a 16-week schedule, an itemized budget of USD 200,000 to 300,000, a weighted scoring model, and a division of responsibilities between the CDMO and the study CRO. The article also clarifies which GMP standard governs drug substance, and closes with recommendations for protecting a sponsor against confidentiality, intellectual property, and copyright exposure in manufacturing engagements.Keywords: request for proposal; GMP; drug substance; CDMO; ICH Q7; ICH Q1A(R2); test article; FDA IND
Authors
- Avinash Dundigalla
- Peivand Pirouzi
- Daxaben Jigneshkumar Patel
- Afeefa Mahmood
- Kritica
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425138
- Primary Topic
- Analytical Methods in Pharmaceuticals
- Type
- article
- Field-Weighted Citation Impact
- 0.00